Soligenix Updates Medical Advisory Board for Cutaneous T-Cell Lymphoma Treatment

Soligenix updates its US Medical Advisory Board for cutaneous T-cell lymphoma, which will provide strategic medical guidance as the company advances the Phase 3 clinical development of HyBryte for the treatment of CTCL. The board is composed of dermatologic and oncologic thought leaders with extensive experience in CTCL. They will contribute to the program, including worldwide regulatory interactions with health authorities and feedback on patient population needs.